Developer docs
API playgroundTry for free, no card

Search company profiles

Tecsomed

Full company profile

uuid000dytv

Namestring
Tecsomed
Legal namestring
Tecsomed
Websiteurl
tecsomed.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Tecsomed is a privately held, pre-launch health technology company developing the myPOM platform, an integrated ecosystem for managing juvenile (Type 1) diabetes. The platform is intended to combine four components: a connected wearable communicator worn by the child, a parental smartphone application for real-time monitoring and alerts, a web portal for data-driven insights, and a lifestyle management module covering behavioral support and disease education. The company states that predictive analytics will be applied to real-time data for early intervention and risk identification, though no technical detail on model architecture, validation, or regulatory clearance has been disclosed.

Tecsomed's go-to-market posture is direct-to-consumer, targeting parents and caregivers of children with Type 1 diabetes who need continuous monitoring and remote communication tools. The planned business model is a recurring subscription for the myPOM platform bundled with the wearable device, though pricing, contract structure, and unit economics are not publicly disclosed. The website remains in a pre-launch state with a mailing list signup for release date updates and a generic contact form, indicating that no commercial product is currently shipping and no revenue is being recognized.

The company is incorporated in the United States, headquartered in Miami Beach, Florida, and operates with a 1-10 person team. No funding rounds, institutional investors, named customers, management team, regulatory submissions, or strategic partnerships are documented in the available data. Market context cited by the company includes 1.25 million Americans with Type 1 diabetes and an associated $14.9 billion in annual US healthcare costs, which frames the addressable opportunity but does not substitute for traction evidence.

Short descriptiontext

Tecsomed is a pre-launch, privately held US health-tech company building the myPOM platform — a connected wearable, parental app, web portal, and lifestyle management module — to help parents of children with juvenile (Type 1) diabetes monitor and manage the condition in real time.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
diabetes management platform, wearable health monitoring, juvenile diabetes care, predictive health analytics, remote patient monitoring
Industry3 codes
PRIMARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLALABAK
Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Digital Health Platform
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1myPOM Platform Subscription
TypeSubscription Recurring
Description

The company offers the myPOM platform as a comprehensive diabetes management solution, likely through a subscription model involving the wearable device and ongoing software access. Details not publicly disclosed.

tecsomed.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2C
B2C
Offering typeSoftware
Software
Brand1 record
1myPOM
Description

Comprehensive diabetes management platform including myPOM Wearable Communicator, myPOM Lifestyle Management, myPOM Parental Smartphone App, and myPOM Web Portal for managing Juvenile Diabetes.

tecsomed.com
Core offering1 text field

Tecsomed develops the myPOM platform, an integrated juvenile diabetes management ecosystem that combines a connected wearable communicator device worn by the child, a parental smartphone application, a web portal, and a lifestyle management module. The platform leverages predictive analytics on real-time data to enable early risk identification, intervention, behavioral management, and disease education for children with Type 1 Diabetes and their parents/caregivers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Reduced healthcare costs through better diabetes management and early intervention
Product overview1 text field

Tecsomed offers the MyPOM platform, a unified diabetes management ecosystem for Juvenile Diabetes consisting of four integrated components: a wearable communicator device worn by the child, a parental smartphone app for real-time monitoring and alerts, a web portal for comprehensive data access, and a lifestyle management module for ongoing disease education and behavioral management. The platform leverages predictive analytics to identify potential risks and enable proactive intervention while facilitating communication between parents and children.

Product and service5 records
1myPOM Platform (Integrated Juvenile Diabetes Management Ecosystem)
CategoryDigital Health Platform / Disease Management Software
Description

Integrated platform for pediatric Type 1 Diabetes management combining wearable, mobile, web, and analytics components for continuous monitoring, parental communication, predictive intervention, and disease education.

2myPOM Wearable Communicator
CategoryWearable Health Device
Description

Child-friendly connected wearable for instant communication, location, and continuous monitoring in children with Juvenile Diabetes.

3myPOM Parental Smartphone App
CategoryMobile Health Application
Description

Smartphone application for parents providing real-time monitoring, alerts, and remote visibility into a child's diabetes metrics via the myPOM wearable.

4myPOM Web Portal
CategoryWeb-based Health Analytics Portal
Description

Web-based dashboard for parents, caregivers, and clinicians providing data-driven insights, longitudinal views, and care coordination tools for pediatric diabetes management.

5myPOM Lifestyle Management
CategoryDisease Education and Behavioral Management Service
Description

Lifestyle and behavioral management module for ongoing disease education, behavioral support, and maintenance activities for children with Juvenile Diabetes and their families.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Market-leading continuous glucose monitor (CGM) manufacturer with FDA-cleared pediatric indications. Both Dexcom and Tecsomed target real-time glucose and lifestyle monitoring for diabetes patients, though Dexcom is an established clinical device.

TypeDirect peer
Description

Maker of FreeStyle Libre CGM, including pediatric versions. Directly comparable as a glucose-monitoring wearable for diabetes with recurring sensor revenue, competing for the same caregiver-driven purchase decisions in T1D households.

TypeDirect peer
Description

Provides Guardian CGM and MiniMed insulin pump systems with pediatric use. Like Tecsomed, targets families managing juvenile diabetes, but with full closed-loop (hybrid closed-loop) systems and deep payor coverage.

TypeDirect peer
Description

Maker of the Omnipod tubeless insulin pump, widely used in pediatric T1D. Comparable because both companies sell wearable diabetes hardware paired with mobile/web software for caregivers managing children with diabetes.

TypeDirect peer
Description

Produces the t:slim X2 insulin pump with Control-IQ technology integrated with CGMs. Similar positioning around real-time data, mobile control, and pediatric diabetes management for parents and caregivers.

TypeDirect peer
Description

Diabetes data management platform that aggregates data from CGMs, pumps, and wearables into a unified dashboard for patients and clinicians. Closest software peer to myPOM's web-portal and predictive-analytics layer.

TypeDirect peer
Description

Consumer diabetes self-management app with logging, bolus estimation, and caregiver features, now part of Roche. Comparable as a smartphone/web companion to CGM/wearables for daily diabetes lifestyle management.

TypeEmerging player
Description

Nonprofit diabetes data platform integrating pumps, CGMs, and apps for patients and clinicians, with strong pediatric and parent-facing tooling. Comparable as a data-driven diabetes management layer for caregivers.

9Bigfoot Biomedical
TypeEmerging player
Description

Developer of smart insulin pen systems and a connected diabetes management platform. Comparable as a digitally enabled diabetes management ecosystem targeting simplified decision support for patients and caregivers.

TypeEmerging player
Description

Maker of the Eversense implantable long-term CGM with a配套 mobile app for continuous monitoring. Comparable as a wearable, connected, caregiver-visible diabetes monitoring solution, though with a more invasive form factor.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tecsomed

Digital Health Platformtecsomed.com

Tecsomed is a pre-launch, privately held US health-tech company building the myPOM platform — a connected wearable, parental app, web portal, and lifestyle management module — to help parents of children with juvenile (Type 1) diabetes monitor and manage the condition in real time.

What Tecsomed does

Tecsomed is a privately held, pre-launch health technology company developing the myPOM platform, an integrated ecosystem for managing juvenile (Type 1) diabetes. The platform is intended to combine four components: a connected wearable communicator worn by the child, a parental smartphone application for real-time monitoring and alerts, a web portal for data-driven insights, and a lifestyle management module covering behavioral support and disease education. The company states that predictive analytics will be applied to real-time data for early intervention and risk identification, though no technical detail on model architecture, validation, or regulatory clearance has been disclosed.

Tecsomed's go-to-market posture is direct-to-consumer, targeting parents and caregivers of children with Type 1 diabetes who need continuous monitoring and remote communication tools. The planned business model is a recurring subscription for the myPOM platform bundled with the wearable device, though pricing, contract structure, and unit economics are not publicly disclosed. The website remains in a pre-launch state with a mailing list signup for release date updates and a generic contact form, indicating that no commercial product is currently shipping and no revenue is being recognized.

The company is incorporated in the United States, headquartered in Miami Beach, Florida, and operates with a 1-10 person team. No funding rounds, institutional investors, named customers, management team, regulatory submissions, or strategic partnerships are documented in the available data. Market context cited by the company includes 1.25 million Americans with Type 1 diabetes and an associated $14.9 billion in annual US healthcare costs, which frames the addressable opportunity but does not substitute for traction evidence.

Tecsomed firmographics

Firmographics
Name
Tecsomed
Legal name
Tecsomed
Website
https://tecsomed.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Tecsomed is a pre-launch, privately held US health-tech company building the myPOM platform — a connected wearable, parental app, web portal, and lifestyle management module — to help parents of children with juvenile (Type 1) diabetes monitor and manage the condition in real time.
Ownership category
akta.pro rank

Tecsomed industry classification

Industry
Product category
Digital Health Platform
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLALABAK
Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)

Keywords

  • Diabetes management platform
  • Wearable health monitoring
  • Juvenile diabetes care
  • Predictive health analytics
  • Remote patient monitoring

Where Tecsomed is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Tecsomed business model

Business model
GTM type
B2C
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. myPOM Platform Subscription: The company offers the myPOM platform as a comprehensive diabetes management solution, likely through a subscription model involving the wearable device and ongoing software access. Details not publicly disclosed.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Tecsomed product offering

Product offering

Core offering

Tecsomed develops the myPOM platform, an integrated juvenile diabetes management ecosystem that combines a connected wearable communicator device worn by the child, a parental smartphone application, a web portal, and a lifestyle management module. The platform leverages predictive analytics on real-time data to enable early risk identification, intervention, behavioral management, and disease education for children with Type 1 Diabetes and their parents/caregivers.

Product overview

Tecsomed offers the MyPOM platform, a unified diabetes management ecosystem for Juvenile Diabetes consisting of four integrated components: a wearable communicator device worn by the child, a parental smartphone app for real-time monitoring and alerts, a web portal for comprehensive data access, and a lifestyle management module for ongoing disease education and behavioral management. The platform leverages predictive analytics to identify potential risks and enable proactive intervention while facilitating communication between parents and children.

Differentiator

Problem solved

Functional benefit

Brands

  • myPOM: Comprehensive diabetes management platform including myPOM Wearable Communicator, myPOM Lifestyle Management, myPOM Parental Smartphone App, and myPOM Web Portal for managing Juvenile Diabetes.

Products and services

  • myPOM Platform (Integrated Juvenile Diabetes Management Ecosystem) Integrated platform for pediatric Type 1 Diabetes management combining wearable, mobile, web, and analytics components for continuous monitoring, parental communication, predictive intervention, and disease education.
  • myPOM Wearable Communicator Child-friendly connected wearable for instant communication, location, and continuous monitoring in children with Juvenile Diabetes.
  • myPOM Parental Smartphone App Smartphone application for parents providing real-time monitoring, alerts, and remote visibility into a child's diabetes metrics via the myPOM wearable.
  • myPOM Web Portal Web-based dashboard for parents, caregivers, and clinicians providing data-driven insights, longitudinal views, and care coordination tools for pediatric diabetes management.
  • myPOM Lifestyle Management Lifestyle and behavioral management module for ongoing disease education, behavioral support, and maintenance activities for children with Juvenile Diabetes and their families.

Quantifiable outcome

  • Reduced healthcare costs through better diabetes management and early intervention

Companies that use Tecsomed

Customer profile

Segments2 records

Ideal customer profiles2 records

Tecsomed technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Tecsomed partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves3 records

Expansion highlights4 records

Tecsomed competitors and assessment

Company assessment

Direct peers

  • Dexcom: Market-leading continuous glucose monitor (CGM) manufacturer with FDA-cleared pediatric indications. Both Dexcom and Tecsomed target real-time glucose and lifestyle monitoring for diabetes patients, though Dexcom is an established clinical device.
  • Abbott Diabetes Care: Maker of FreeStyle Libre CGM, including pediatric versions. Directly comparable as a glucose-monitoring wearable for diabetes with recurring sensor revenue, competing for the same caregiver-driven purchase decisions in T1D households.
  • Medtronic Diabetes: Provides Guardian CGM and MiniMed insulin pump systems with pediatric use. Like Tecsomed, targets families managing juvenile diabetes, but with full closed-loop (hybrid closed-loop) systems and deep payor coverage.
  • Insulet Corporation: Maker of the Omnipod tubeless insulin pump, widely used in pediatric T1D. Comparable because both companies sell wearable diabetes hardware paired with mobile/web software for caregivers managing children with diabetes.
  • Tandem Diabetes Care: Produces the t:slim X2 insulin pump with Control-IQ technology integrated with CGMs. Similar positioning around real-time data, mobile control, and pediatric diabetes management for parents and caregivers.
  • Glooko: Diabetes data management platform that aggregates data from CGMs, pumps, and wearables into a unified dashboard for patients and clinicians. Closest software peer to myPOM's web-portal and predictive-analytics layer.
  • mySugr (Roche): Consumer diabetes self-management app with logging, bolus estimation, and caregiver features, now part of Roche. Comparable as a smartphone/web companion to CGM/wearables for daily diabetes lifestyle management.

Emerging players

  • Tidepool: Nonprofit diabetes data platform integrating pumps, CGMs, and apps for patients and clinicians, with strong pediatric and parent-facing tooling. Comparable as a data-driven diabetes management layer for caregivers.
  • Bigfoot Biomedical: Developer of smart insulin pen systems and a connected diabetes management platform. Comparable as a digitally enabled diabetes management ecosystem targeting simplified decision support for patients and caregivers.
  • Senseonics (Eversense): Maker of the Eversense implantable long-term CGM with a配套 mobile app for continuous monitoring. Comparable as a wearable, connected, caregiver-visible diabetes monitoring solution, though with a more invasive form factor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Tecsomed social profiles

Digital presence

Tecsomed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tecsomed leadership team

Management profile

Number of profiles

Tecsomed funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tecsomed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tecsomed

What does Tecsomed do?

Tecsomed develops the myPOM platform, an integrated juvenile diabetes management ecosystem that combines a connected wearable communicator device worn by the child, a parental smartphone application, a web portal, and a lifestyle management module. The platform leverages predictive analytics on real-time data to enable early risk identification, intervention, behavioral management, and disease education for children with Type 1 Diabetes and their parents/caregivers.

Is Tecsomed a public or private company?

Tecsomed is a private company. It is classified as unknown and is currently operating.

When was Tecsomed founded?

Tecsomed was founded in 2016. It employs 1 to 10 people.

Where is Tecsomed based?

Tecsomed is headquartered in San Diego, United States, in the North America region.

How does Tecsomed make money?

One revenue line is on record: myPOM Platform Subscription.

Who are Tecsomed's main competitors?

Direct peers on record are Dexcom, Abbott Diabetes Care, Medtronic Diabetes, Insulet Corporation, Tandem Diabetes Care, Glooko and mySugr (Roche). Emerging players are Tidepool, Bigfoot Biomedical and Senseonics (Eversense).

Does Tecsomed have an API?

No public API is recorded for Tecsomed.

What industry is Tecsomed in?

Tecsomed's product category is Digital Health Platform. Its primary akta.pro industry code is HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables), with a secondary code of HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators). Its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales